Quigley to tap into OTC market

DOYLESTOWN, Pa. Quigley plans to focus on product developments in the over-the-counter arena, as opposed to developing prescription drug products, the company announced Thursday.

Though Quigley will continue to pursue the prescription-only development of QR333, a medicine for the symptomatic relief of diabetic peripheral neuropathy; QR440, a remedy for relief of inflammation and joint pain; and QR448, an anti-infective against infectious bronchitis in poultry.

Ted Karkus, Quigley chairman and CEO, suggested that Quigley would be placing the lion’s share of its investment behind brand development of Cold-Eeze. “We are particularly interested in leveraging our distribution network in mass, pharmacy and grocery retail by acquiring or developing additional personal care and OTC products,” he said. “We are aggressively searching for product acquisitions and researching line extensions of our Cold-Eeze and Kids-Eeze brands to accomplish these goals, diversify our product offerings and to set the stage for future growth of our company.”